Highland Capital Management (Tennessee)’s Takeda Pharmaceutical TAK Stock Holding History

Highland Capital Management (Tennessee)’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$877K	Buy	54,700 +100	+0.2%	+$1.66K	0.04%	247
2026 Q1	$1.01M	Sell	54,600 -200	-0.4%	-$3.51K	0.05%	236
2025 Q4	$854K	Sell	54,800 -6,850	-11%	-$97.9K	0.04%	244
2025 Q3	$903K	Buy	61,650 +400	+0.7%	+$5.94K	0.05%	254
2025 Q2	$947K	Sell	61,250 -1,650	-3%	-$24.4K	0.05%	238
2025 Q1	$935K	Sell	62,900 -4,800	-7%	-$67.3K	0.06%	238
2024 Q4	$896K	Buy	67,700 +6,050	+10%	+$83.1K	0.05%	231
2024 Q3	$877K	Sell	61,650 -150	-0.2%	-$2.13K	0.05%	241
2024 Q2	$800K	Sell	61,800 -5,300	-8%	-$70.2K	0.05%	237
2024 Q1	$932K	Hold	67,100	–	–	0.05%	239
2023 Q4	$958K	Hold	67,100	–	–	0.06%	233
2023 Q3	$1.04M	Sell	67,100 -700	-1%	-$10.8K	0.07%	220
2023 Q2	$1.07M	Buy	+67,800	New	+$1.11M	0.07%	223

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Highland Capital Management (Tennessee)'s TAK Position: Q2 2026 in Review

Highland Capital Management (Tennessee) increased its Takeda Pharmaceutical (TAK) stake by 0.18% in Q2 2026, buying an estimated $1.66K and bringing the position to 54,700 shares worth $877K. The position accounts for 0.04% of the portfolio, ranked #247.

Highland Capital Management (Tennessee) first reported a position in TAK in Q2 2023 and has held it in 13 quarters since. The position peaked at $1.07M in Q2 2023. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

Highland Capital Management (Tennessee) held 54,700 shares of Takeda Pharmaceutical worth $877K as of Q2 2026.
Highland Capital Management (Tennessee) bought 100 Takeda Pharmaceutical shares in Q2 2026, an estimated $1.66K.
Takeda Pharmaceutical made up 0.04% of Highland Capital Management (Tennessee)'s portfolio in Q2 2026, its #247 holding.
Highland Capital Management (Tennessee) first reported a position in Takeda Pharmaceutical in Q2 2023 and has held it in 13 quarters since.
Highland Capital Management (Tennessee)'s Takeda Pharmaceutical position peaked at $1.07M in Q2 2023.
376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Highland Capital Management (Tennessee)'s 13F filing for Q2 2026, filed 21 Jul 2026.